Overall, our study revealed that the YTHDF1–m6A–FTH axis participates in the progression of lung adenocarcinoma, suggesting the pathway axis might be a novel therapeutic target for lung adenocarcinoma treatment. The gene discussed is FTH1; the disease is lung adenocarcinoma.